Nexgel: Adam R. Levy proposes 227,956-share sale
Levy's notice identifies open-market purchases and stock grants as equity compensation as acquisition methods from October 1, 2019 through January 1, 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
NEXGEL, Inc. (NXGL) affiliate Adam R. Levy reported a proposed sale of 227,956 common shares, with an approximate sale date of September 30, 2026. His remarks also describe a late-filed proposed sale of 21,500 shares as of September 29, 2026; a separate past-three-months table entry lists 21,500 common shares dated September 29, 2026.
The securities information pairs the 227,956-share entry with an aggregate market value of $41,214.00 and the 21,500-share entry with $3,488.98. It lists Charles Schwab & Co., Inc. as broker and Nasdaq as the market. Levy's reported acquisition methods include open-market purchases and stock grants as part of equity compensation from October 1, 2019 through January 1, 2025.
Key Figures
Key Terms
Rule 144 regulatory
Affiliate regulatory
equity compensation financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.